Dec 15 (Reuters) - CSL Ltd (CSL) :
- GARADACIMAB RECEIVES FDA AND EMA FILING ACCEPTANCE
- ORPHAN-DRUG DESIGNATION FOR GARADACIMAB AS A THERAPY FOR HEREDITARY ANGIOEDEMA GRANTED BY BOTH FDA AND EMA
(([email protected];))
News: CSL CSL Ltd Says Garadacimab Received FDA And EMA Filing Acceptance
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$255.47 |
Change
-1.910(0.74%) |
Mkt cap ! $123.5B | |||
| Open | High | Low | Value | Volume |
| $256.32 | $256.50 | $252.60 | $119.1M | 467.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 486 | $255.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $255.48 | 24 | 4 |
View Market Depth
| Last trade - 15.40pm 21/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |